A team at Soochow University in China has described a peptide-based carrier that delivers a microRNA to steroid-damaged bone. The work was published in Nature Communications on 5 November 2026. It was done in rats, and nothing here has been tested in people.
The problem
Glucocorticoids, the steroids used to control inflammation, can cause severe bone loss and osteonecrosis, the death of bone tissue, when taken over long periods. The journal's summary says the aim was to limit that bone loss and support the recovery of the blood vessels that feed the bone.
What they built
The carrier is a peptide-oligonucleotide nanohybrid, which the authors call PON. A peptide shell is joined to a short strand of RNA, in this case miR-26a-5p, a microRNA already known from earlier bone studies to support bone formation. The paper's title calls the design pathology-adapted, meaning it is built to respond to the conditions in injured bone.
The same group, with Dechun Geng and Yi Qin among the authors, reported an earlier PON for rheumatoid arthritis in Advanced Materials in 2025. That version carried a different microRNA and was described as combining targeted delivery to inflamed tissue, entry into cells and escape from the cell's recycling compartments.
What it did in rats
According to the authors, the peptide coat helps the particles find injured bone, enter cells and escape the cell's recycling machinery before the cargo is released. Once inside, miR-26a-5p reduced the activity of GSK-3β and helped stabilise HIF-1α, which kept bone-building and blood-vessel signals working together.
In rats with glucocorticoid-induced bone loss, PON given through the bloodstream limited early damage to bone and blood vessels. The authors also report that it slowed further decline after the disease was already established.
What is still unknown
OrientSciences has worked from the journal's published summary and the authors' description, and has not reviewed the full text, so doses, group sizes and effect sizes are not reported here. Rat models of steroid-induced bone loss do not always carry over to patients, and no safety data in humans exist for this carrier.
Delivery is the long-standing obstacle for microRNA treatments. Earlier work, including a 2016 Nature Communications study that placed miR-26a in a bone scaffold and linked it to GSK-3β, showed the microRNA is active in bone. This study is an attempt to get it there through the blood.